UCART19-Paediatric Acute Lymphoblastic Leukaemia (PALL) Study
IRB
CHLA-18-00378
UCART19-Paediatric Acute Lymphoblastic Leukaemia (PALL) Study: A phase 1, open label, non-comparative, study to evaluate the safety and the ability of UCART19 to induce molecular remission in paediatric patients with relapsed /refractory Bcell acute lymphoblastic leukaemia
CD19 is a B-cell surface protein expressed throughout B cell development; therefore, it is expressed on nearly all B cell malignancies, including acute lymphoblastic leukemia (ALL),and many non-Hodgkin lymphomas. B cell neoplasms are clonal tumors of mature and immature B lymphocytes (e.g., acute lymphoblastic leukemia).UCART19 is intended to treat CD19-positive B lymphoid malignancies in paediatric and adult populations.